Patients age 18 years with locally advanced , metastatic , or recurrent advanced nonsquamous non-small-cell lung cancer ( NSCLC ) were randomly assigned to receive carboplatin ( area under the curve , 6 ) intravenously and paclitaxel ( 175 mg/m ( 2 ) ) intravenously ( CP ) on day 1 of each 3-week cycle , for six cycles , plus placebo ( Pl + CP ) or bevacizumab ( B+CP ) 15 mg/kg intravenously , on day 1 of each cycle , until progression , unacceptable toxicity , or death .